Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With <scp>HR</scp>+/<scp>HER2</scp>− Metastatic Breast Cancer

Authors

Benjamin Li (ORCID: https://orcid.org/0000-0002-1783-7013)
Elizabeth Esterberg (ORCID: https://orcid.org/0000-0003-0780-4776)
Rickard Sandin
Adam Brufsky (ORCID: https://orcid.org/0000-0001-8080-7960)
Doris Makari
Stella Stergiopoulos (ORCID: https://orcid.org/0000-0001-6868-0493)
Siddharth Karanth (ORCID: https://orcid.org/0000-0002-4923-2692)
RK Goyal (ORCID: https://orcid.org/0000-0003-1632-036X)
Sean D. Candrilli (ORCID: https://orcid.org/0000-0002-2062-1192)
Hope S. Rugo (ORCID: https://orcid.org/0000-0001-6710-4814)
Connie Chen (ORCID: https://orcid.org/0000-0001-5384-4707)

Institutions

University of Pittsburgh (US)
University of California, San Francisco (US)
Pfizer (United States) (US)
Triangle (US)
Pfizer (Sweden) (SE)
RTI Health Solutions (US)

Publication Details

Journal: Cancer Medicine
Published: 2025-03-27
DOI: https://doi.org/10.1002/cam4.70719
Primary Topic: Advanced Breast Cancer Therapies
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Pfizer

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer

Benjamin Li, Elizabeth Esterberg, Rickard Sandin, Adam Brufsky et al.

Mar 27, 2025

Cancer Medicine

Advanced Breast Cancer Therapies

article

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer

Benjamin Li, Elizabeth Esterberg, Rickard Sandin, Adam Brufsky, Doris Makari, Stella Stergiopoulos, Siddharth Karanth, RK Goyal, Sean D. Candrilli, Hope S. Rugo, Connie Chen

March 27, 2025article en

Abstract

No abstract available for this paper.

Cancer MedicineVol. 14(7)

University of Pittsburgh (US), University of California, San Francisco (US), Pfizer (United States) (US), Triangle (US), Pfizer (Sweden) (SE), RTI Health Solutions (US)

Pfizer

Openalex Percentile: Top 91%

Advanced Breast Cancer Therapies

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With <scp>HR</scp>+/<scp>HER2</scp>− Metastatic Breast Cancer — Benjamin Li, Elizabeth Esterberg, et al. · Cancer Medicine (2025) | TGRS Research Map | TGRS